- €982.29m
- €1.21bn
- €424.66m
Brief: GVS FY Net Profit EUR 33.4 Mln
Brief: GVS Executes Capital Increase Of EUR 75 Mln Reserved To GVS Group
Brief: Gvs Board Approves EUR 75 Mln Capital Increase Reserved For Gvs Group
Brief: Haemonetics Announces Sale Of Whole Blood Assets To Gvs for Up To $67.1 Mln
Brief: GVS To Buy Haemonetics' Whole Blood Business For $44.6 Mln
Brief: Gvs 9M Adj. Net Profit EUR 33.9 Mln
Brief: GVS 9M Revenue EUR 321.7 Million
Brief: GVS H1 Adj EBITDA EUR 52.0 Mln
Brief: GVS H1 Revenue EUR 214.8 Million
Brief: GVS Q1 Revenue EUR 103.9 Million
Brief: GVS Q1 Net Profit Up To EUR 9.4 Mln
Brief: GVS To Build Facility For Fabrication Of Diaphragm For Green Hydrogen Production
Brief: GVS FY Adj. EBITDA Slightly Beats Consensus
Brief: Gvs FY Net Profit Down To eUR 13.6 Mln
Brief: Gvs 9-Month Net Profit Down To EUR 15.8 Mln
Brief: GVS Sees 2025 Adj. EBITDA Margin Between 27-28%
Brief: GVS H1 Net Profit Down To EUR 7.3 Mln
GVS drops after GS cuts stock to 'sell' on high leverage, lower forecasts
Brief: GVS Q1 Adj. Net Profit Down To EUR 6.1 Mln